惠泰医疗
(688617)
| 流通市值：336.77亿 | | | 总市值：336.77亿 |
| 流通股本：6686.14万 | | | 总股本：6686.14万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 455,327,284.53 | 1,650,211,802.94 | 1,213,709,560.43 | 787,985,502.65 |
| 营业收入 | 455,327,284.53 | 1,650,211,802.94 | 1,213,709,560.43 | 787,985,502.65 |
| 二、营业总成本 | 308,517,516.93 | 1,115,967,317.51 | 822,000,174.52 | 523,171,556.86 |
| 营业成本 | 127,424,624.56 | 474,179,431.43 | 347,387,027.12 | 222,734,109.67 |
| 税金及附加 | 5,832,696.89 | 20,172,183.48 | 15,622,586.82 | 10,467,276.09 |
| 销售费用 | 87,850,013.39 | 304,699,420.48 | 233,011,858.56 | 150,741,351.67 |
| 管理费用 | 24,257,646.37 | 82,257,265.37 | 62,140,662.62 | 35,493,379.63 |
| 研发费用 | 65,615,307.81 | 237,915,622.41 | 168,316,723.06 | 108,927,553.62 |
| 财务费用 | -2,462,772.09 | -3,256,605.66 | -4,478,683.66 | -5,192,113.82 |
| 其中:利息费用 | 713,208.4 | 3,688,666.91 | 3,083,158.12 | 2,224,495.86 |
| 其中:利息收入 | 3,131,697.04 | 4,605,675.08 | 3,253,631.76 | 2,183,395.76 |
| 加:公允价值变动收益 | 897,597.82 | - | 3,229,316.61 | 1,437,915.48 |
| 加:投资收益 | 3,346,584.4 | 23,131,895.54 | 16,544,215.01 | 14,574,004.26 |
| 资产处置收益 | -697.13 | 11,965,748.93 | 11,959,189.03 | 69,724.77 |
| 资产减值损失(新) | 90,078.49 | -15,803,744.29 | 4,144,284.53 | 871,362.58 |
| 信用减值损失(新) | -44,944.89 | 464,856.16 | -46,412.26 | 886,011.87 |
| 其他收益 | 6,886,051.79 | 46,411,460.96 | 27,472,679.45 | 9,556,150.21 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 157,984,438.08 | 600,414,702.73 | 455,012,658.28 | 292,209,114.96 |
| 加:营业外收入 | 49,503.53 | 620,913.33 | 618,158.37 | 12,870.38 |
| 减:营业外支出 | 352,137.71 | 4,667,824.5 | 1,480,841.44 | 1,021,743.23 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 157,681,803.9 | 596,367,791.56 | 454,149,975.21 | 291,200,242.11 |
| 减:所得税费用 | 19,822,317.74 | 74,237,524.92 | 57,586,607.44 | 38,565,693.44 |
| 六、净利润 | 137,859,486.16 | 522,130,266.64 | 396,563,367.77 | 252,634,548.67 |
| 持续经营净利润 | 137,859,486.16 | 522,130,266.64 | 396,563,367.77 | 252,634,548.67 |
| 归属于母公司股东的净利润 | 140,143,827.76 | 533,924,244 | 403,247,364.38 | 257,395,456.84 |
| 少数股东损益 | -2,284,341.6 | -11,793,977.36 | -6,683,996.61 | -4,760,908.17 |
| (一)基本每股收益 | 2.1 | 8.04 | 6.04 | 3.86 |
| (二)稀释每股收益 | 2.07 | 7.92 | 5.95 | 3.8 |
| 八、其他综合收益 | -37,888.78 | 7,747,168.37 | 14,190,150.96 | 14,259,714.32 |
| 归属于母公司股东的其他综合收益 | -37,888.78 | 7,747,168.37 | 14,190,150.96 | 14,259,714.32 |
| 九、综合收益总额 | 137,821,597.38 | 529,877,435.01 | 410,753,518.73 | 266,894,262.99 |
| 归属于母公司股东的综合收益总额 | 140,105,938.98 | 541,671,412.37 | 417,437,515.34 | 271,655,171.16 |
| 归属于少数股东的综合收益总额 | -2,284,341.6 | -11,793,977.36 | -6,683,996.61 | -4,760,908.17 |
| 公告日期 | 2024-04-26 | 2024-03-25 | 2023-10-27 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |